US gene therapy CDMO, Andelyn Biosciences, has opened a new GMP clinical and commercial manufacturing facility to support cell and gene therapy (CGT) development and manufacturing.
Charles River Laboratories International has launched a new AAV based platform that it claims has the capability to reduce time from process development to GMP by 55% and deliver a drug product in fewer than eight months.
Univercells Technologies has completed €2m expansion of its Nivelles, Belgium site, with the goal of boosting supply chain security for biomanufacturers.
The US Food and Drug Administration (FDA) has approved Kite’s retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
Fujifilm Diosynth Biotechnologies (FDB) said the expansion of its large-scale microbial manufacturing facility at the Billingham campus in the north-east of England, has got underway.
Almost all of Australia’s vaccines are imported: creating a potential crisis in a pandemic. As a result, the country is setting out its strategy for developing vaccine manufacturing capabilities.
Ncardia’s cell therapy development and manufacturing business Cellistic will acquire Celyad Oncology’s GMP grade cell therapy manufacturing capability, covering Celyad’s Mont-Saint-Guibert facility in Belgium and all related staff.
Orca Bio, a biotech developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, will expand its current manufacturing capabilities with the construction of a new 100,000-square-foot commercial...
Biotimize has announced the opening of a $30m Series A fundraising round: with the investment set to enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America.
RoosterBio has entered into an exclusive distributor partnership with MBL Beijing Biotech: with RoosterBio’s expansion media, exosome collection media, bioreactor media and genetic engineering media to be sold and distributed by MBL Beijing and thus becoming...
Despite continuous bioprocessing being talked about as the future of manufacturing in biologics for years, this has not become reality. However, in recent years, the US government has begun to dedicate funds to intensify the production of biologics.
ElevateBio and the University of Pittsburgh have entered into a long-term strategic partnership to accelerate the development of innovative cell and gene therapies: with ElevateBio to locate its next BaseCamp process development and GMP manufacturing...
As part of its strategy for growth in the biopharmaceutical industry, Trelleborg Healthcare & Medical will make an investment of several million dollars in expanding its manufacturing facility and BioPharma Center of Excellence in Northborough, Massachusetts....
AGC Biologics and RoosterBio have launched a strategic partnership to create an end-to-end solution for the development and production of hMSC and exosome therapeutics.
Biomanufacturing company National Resilience has announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
Charles River Laboratories, International Inc. has received regulatory approval - in the form of Good Manufacturing Practice (GMP) certification - to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European...
Millipore Sigma has launched its VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform: meaning the CDMO can now provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development.
Pfizer is planning to deliver COVID-19 vaccines against two sets of omicron subvariants in the autumn in the belief its “robust manufacturing capabilities” are up to the task.
Edinburgh CDMO RoslinCT and Massachusetts CDMO Lykan Bioscience will combine to create a global advanced therapies CDMO: offering significantly expanded manufacturing capacity.
A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.
GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companies’ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.
Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.
CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.
SK bioscience has extended its partnership with Novavax to include the manufacture and supply of Novavax’s Omicron COVID-19 vaccine candidate, which could become available later this year.
Wacker Biotech’s site in Halle, Germany will be expanded in the coming months into a competence center for actives based on messenger ribonucleic acid (mRNA).
Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).
Construction works on an mRNA manufacturing facility have started in Kigali, Rwanda: as BioNTech works to create a pan-African end-to-end manufacturing network for mRNA-based vaccines.
VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.
Umoja Biopharma and TreeFrog Therapeutics have formed an alliance to address challenges facing ex vivo allogeneic therapies in immuno-oncology, including issues scaling up production to reach all patients.
Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A.
Evonik will build a production facility for pharmaceutical lipids in Indiana: with the new site ‘positioning the group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines’.
CDMO CordenPharma has increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy: with a €10m ($10.7m) investment in new Lipid Nanoparticle (LNP) formulation, development and production areas.
The agreement, which was made in coordination between the US army and BARDA, will see Jubilant expand its injectable filling production capacity to prepare for future pandemics.
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
